Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Headache|November 2, 2019
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic MigrainePaul K Winner, Egilius L H Spierings, Paul P Yeung, et al.Drug Safety|May 19, 2019
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL StudyPaul K Winner, Andrew M Blumenfeld, Eric J Eross, et al.The Journal of Headache and Pain|February 8, 2022
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF studyPeter McAllister, Paul K Winner, Jessica Ailani, et al.Headache|July 30, 2011
Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescentsSusan A McDonald, Andrew D Hershey, Eric Pearlman, et al.Lancet (London, England)|November 28, 2008
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialTony W Ho, Michel D Ferrari, David W Dodick, et al.Headache|February 9, 2022
Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendationsStewart J Tepper, Huma U Sheikh, Carrie O Dougherty, et al.Headache|July 31, 2016
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine PatientsDikla Gutman, Edward Hellriegel, Ernesto Aycardi, et al.Pediatrics|May 16, 2012
Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraineFrederick J Derosier, Donald Lewis, Andrew D Hershey, et al.Journal of the American Academy of Child and Adolescent Psychiatry|August 7, 2002
GW320659 for the treatment of attention-deficit/hyperactivity disorder in childrenJoseph DeVeaugh-Geiss, C Keith Conners, Elias H Sarkis, et al.Neurology|December 20, 2019
Vascular safety of erenumab for migraine preventionDavid Kudrow, Julio Pascual, Paul K Winner, et al.Pageof 3